-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ViiV Healthcare, a subsidiary of GlaxoSmithKline, announced that its february long-acting injection Cabotegravir, which prevents HIV, has been named the U.S. Food and Drug Administration's (FDA) Breakthrough Therapy (BTD).
BTD is based on the results of the IIb/III HPTN 083 trial, which compared cabogravir with the standard pre-exposure prophylactic drug (PrEP) for HIV - the daily oral drug Truvada (FTC/TDF, entourage/ginolfovir, 200mg/300mg tablets) for HIV prevention.
results showed that cabotegravir was 66 percent more effective at preventing HIV than daily oral FTC/TDF tablets, 0.41 percent in cabotegravir and 1.22 percent in FTC/TDF.
: According to ViiV, about 38 million people are currently living with HIV, with 1.7 million new cases reported by the end of 2019.